Track and trace dies in final FDA reauthorization bill talks

Track and trace has apparently been trashed, at least for now. Unable to agree on details between what the FDA was seeking and what the industry was willing to sign off on, the plan to finally create a nationwide system that could identify and follow individual drugs through a serpentine supply chain got left on the negotiating floor, Reuters reports, citing anonymous sources. The plan was to be a part of the FDA user fee reauthorization bill that Congress has been reconciling, one of the few pieces of legislation with bipartisan support in this tense pre-election session. The staffer said some lawmakers may try to introduce the measure as a stand-alone bill later this year. But the legislation may have a hard time making it through a divided Congress. Story | More

Suggested Articles

McCallum was hit with a warning letter from the FDA for testing issues with its products and failing to keep appropriate records.

The FDA made public a voluntary recall of sterile injectables made by Coastal Meds of Mississippi, after visible particles were found in some vials.

It’s been a strange road for BMS' Opdivo-Yervoy combo in first-line kidney cancer, but the New Jersey drugmaker finally has a go-ahead.